Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | GLP1R | P43220 | 8/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23945859 | 0.91 | MEN1 (0.40) | MEN1KMT2ATSHRUSP2HDAC7 | |
| SCHEMBL25704881 | 0.86 | MEN1 (0.50) | MEN1KMT2ATSHRGLP1RSMN1; SMN2 | |
| SCHEMBL25827160 | 0.82 | MEN1 (0.53) | MEN1KMT2ATSHRUSP2GLP1R | |
| SCHEMBL25466881 | 0.82 | MEN1 (0.53) | MEN1KMT2ATSHRUSP2GLP1R | |
| SCHEMBL21105932 | 0.82 | KMT2A (0.59) | MEN1KMT2ATSHRUSP2GLP1R | |
| SCHEMBL21105478 | 0.82 | KMT2A (0.59) | MEN1KMT2ATSHRUSP2GLP1R | |
| SCHEMBL25546667 | 0.82 | KMT2A (0.59) | MEN1KMT2ATSHRUSP2GLP1R | |
| SCHEMBL22837635 | 0.82 | KMT2A (0.59) | MEN1KMT2ATSHRUSP2GLP1R | |
| SCHEMBL25925118 | 0.81 | USP2 (0.47) | MEN1KMT2ATSHRUSP2GLP1R | |
| SCHEMBL25831763 | 0.80 | KMT2A (0.50) | MEN1KMT2ATSHRGLP1RSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11679109-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | MEN1 2085/4885KMT2A 73/4885TSHR 4388/4885 |
| US-11679109-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCA2, SMARCC2 | MEN1 2085/4885KMT2A 73/4885TSHR 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.